GW Pharmaceuticals PLC (NASDAQ:GWPH) Position Cut by Airain ltd

Airain ltd lessened its stake in shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) by 28.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,469 shares of the biopharmaceutical company’s stock after selling 5,472 shares during the quarter. Airain ltd owned about 0.05% of GW Pharmaceuticals PLC worth $1,350,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in GWPH. Victory Capital Management Inc. boosted its stake in shares of GW Pharmaceuticals PLC by 9.2% during the second quarter. Victory Capital Management Inc. now owns 308,945 shares of the biopharmaceutical company’s stock valued at $30,971,000 after acquiring an additional 25,920 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of GW Pharmaceuticals PLC by 5.2% during the second quarter. Jennison Associates LLC now owns 490,721 shares of the biopharmaceutical company’s stock valued at $49,195,000 after acquiring an additional 24,376 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new stake in shares of GW Pharmaceuticals PLC during the second quarter valued at $163,000. Alps Advisors Inc. boosted its stake in shares of GW Pharmaceuticals PLC by 4.9% during the second quarter. Alps Advisors Inc. now owns 22,840 shares of the biopharmaceutical company’s stock valued at $2,290,000 after acquiring an additional 1,071 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in shares of GW Pharmaceuticals PLC by 49.2% during the second quarter. DekaBank Deutsche Girozentrale now owns 10,920 shares of the biopharmaceutical company’s stock valued at $1,091,000 after acquiring an additional 3,600 shares during the last quarter. Hedge funds and other institutional investors own 75.07% of the company’s stock.

A number of brokerages have issued reports on GWPH. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. Zacks Investment Research upgraded GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price objective on the stock in a report on Monday, July 17th. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, ValuEngine upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. GW Pharmaceuticals PLC currently has a consensus rating of “Buy” and an average price target of $148.55.

ILLEGAL ACTIVITY WARNING: “GW Pharmaceuticals PLC (NASDAQ:GWPH) Position Cut by Airain ltd” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/09/17/airain-ltd-has-1-35-million-position-in-gw-pharmaceuticals-plc-gwph.html.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded up 1.02% during midday trading on Friday, reaching $108.23. The company’s stock had a trading volume of 239,954 shares. The stock’s 50-day moving average is $105.92 and its 200 day moving average is $110.11. The stock’s market capitalization is $2.74 billion. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.34). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period in the previous year, the firm posted ($0.05) EPS. On average, analysts expect that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply